Ingredients and medical food company, Enzymotec Ltd (NASDAQ:ENZY), is plummeting in the market by a high of 28.57% after the company reported its first quarter unaudited financial results. During the quarter, the company signed a settlement and license agreement with Neptune Technologies & Bio resources. It also completed the repayment of its long-term loan subject to financial and other covenants. Enzymotec Ltd (NASDAQ:ENZY), net profit margin is 11.70% and weekly performance is -29.16%. On last trading day company shares ended up $13.75. Analysts mean target price for the company is $29.00. Enzymotec Ltd (NASDAQ:ENZY), distance from 50-day simple moving average (SMA50) is -38.58%.
Hanwha Solarone Co Ltd (NASDAQ:HSOL), reported its unaudited financial results for the three months ended March 31, 2014. Total net revenues were RMB1, 138.4 million (US$183.1 million), a decrease of 12.1% from RMB1, 294.9 million in 4Q13, and an increase of 2.3% from RMB1, 112.9 million in 1Q13. The decrease in total net revenues in 1Q14 compared with 4Q13 was primarily due to lower shipments. Hanwha Solarone Co Ltd (NASDAQ:HSOL), fell 10.51% in last trading session and ended the day on $2.47. HSOL, Gross Margin is -2.60% and its return on assets is -16.30%. Hanwha Solarone Co Ltd (NASDAQ:HSOL), quarterly performance is -9.19%.
Pacific Ethanol Inc (NASDAQ:PEIX), the leading producer and marketer of low-carbon renewable fuels in the Western United States, announced it will present at the 15th Annual B. Riley & Co. Investor Conference at 2:30 p.m. PT on Tuesday, May 20, 2014 at the Loews Santa Monica Beach Hotel. Pacific Ethanol Inc (NASDAQ:PEIX), shares moved down 5.18% in last trading session and was closed at $10.99, while trading in range of $10.84 – 11.49. Pacific Ethanol Inc (NASDAQ:PEIX), year to date (YTD) performance is 115.91%.
On May 12, 2014, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), reported its 1Q14 earnings for the quarter ended March 31, 2014. The company reported wider net loss for 1Q14 at $16.1 million ($0.17 per share) as compared to a net loss of $11.7 million ($0.14 per share) for 1Q13. The company reported cash equivalents, marketable securities and interest receivable at $144.7 million as at March 31, 2014. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), ended the last trading day at $2.70. Company weekly volatility is calculated as 8.43% and price to cash ratio as 2.14.
Deutsche Telekom AG (ADR) (OTCMKTS:DTEGY), wants to be compensated by Sprint Corp (S.N) in the event its planned merger with the German firm’s T-Mobile US Inc (TMUS.N) does not win regulatory approval, the Wall Street Journal reported, citing people familiar with the matter. Deutsche Telekom AG (ADR) (OTCMKTS:DTEGY), on last trading day company shares ended up $16.82.
Leave a Reply